Evidence map›Paper›PMID 18301755›Full record

ArticlePloS one2008

One-pot, mix-and-read peptide-MHC tetramers.

Christian Leisner, Nina Loeth, Kasper Lamberth, Sune Justesen, Christina Sylvester-Hvid, Esben G Schmidt, Mogens Claesson, Soren Buus, Anette Stryhn

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 97 citations in OpenAlex.

  1. Trial
  2. HLA-B*14:02-Restricted Env-Specific CD8Journal of virology · 2017
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Delivery ofFrontiers in immunology · 2023
    Article
  8. Article
  9. CD8Diabetes · 2021
    Article
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Review
  15. A Systematic, Unbiased Mapping of CD8Frontiers in immunology · 2020
    Article
  16. Molecular therapy. Methods & clinical development · 2019
    Article
  17. Article
  18. Determinants for Neoantigen Identification.Frontiers in immunology · 2019
    Review
  19. Article
  20. Islet-reactive CD8Science immunology · 2018
    Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Christian LeisnerLaboratories of Experimental Immunology, University of Copenhagen, Copenhagen, Denmark.
Nina Loeth
Kasper Lamberth
Sune Justesen
Christina Sylvester-Hvid
Esben G Schmidt
Mogens Claesson
Soren Buus
Anette Stryhn
University of Copenhagen · DK

Funding

NCCDPHP CDC HHS U58 DP006015PHS HHS 266200400025C
6 · The paper itself

Abstract

backgroundCytotoxic T Lymphocytes (CTL) recognize complexes of peptide ligands and Major Histocompatibility Complex (MHC) class I molecules presented at the surface of Antigen Presenting Cells (APC). Detection and isolation of CTL's are of importance for research on CTL immunity, and development of vaccines and adoptive immune therapy. Peptide-MHC tetramers have become important reagents for detection and enumeration of specific CTL's. Conventional peptide-MHC-tetramer production involves recombinant MHC production, in vitro refolding, biotinylation and tetramerization; each step followed by various biochemical steps such as chromatographic purification, concentration etc. Such cumbersome production protocols have limited dissemination and restricted availability of peptide-MHC tetramers effectively precluding large-scale screening strategies involving many different peptide-MHC tetramers. METHODOLOGY/PRINCIPAL

findingsWe have developed an approach whereby any given tetramer specificity can be produced within 2 days with very limited effort and hands-on time. The strategy is based on the isolation of correctly oxidized, in vivo biotinylated recombinant MHC I heavy chain (HC). Such biotinylated MHC I HC molecules can be refolded in vitro, tetramerized with streptavidin, and used for specific T cell staining-all in a one-pot reaction without any intervening purification steps. CONCLUSIONS/SIGNIFICANCE: We have developed an efficient "one-pot, mix-and-read" strategy for peptide-MHC tetramer generation, and demonstrated specific T cell straining comparable to a commercially available MHC-tetramer. Here, seven peptide-MHC tetramers representing four different human MHC (HLA) class I proteins have been generated. The technique should be readily extendable to any binding peptide and pre-biotinylated MHC (at this time we have over 40 different pre-biotinylated HLA proteins). It is simple, robust, and versatile technique with a very broad application potential as it can be adapted both to small- and large-scale production of one or many different peptide-MHC tetramers for T cell isolation, or epitope screening.

Indexed as

Immunologic TechniquesMajor Histocompatibility ComplexBiotinylationEpitope MappingHistocompatibility Antigens Class IHumansMethodsPeptidesStreptavidinT-Lymphocytes, CytotoxicHistocompatibility Antigens Class IPeptidesStreptavidin

Identifiers

PMID18301755
PMCPMC2244712
OpenAlexW2043722716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.